Bispecific Monoclonal Antibody Therapy of B-Cell Malignancy

References

• Kaminski M. S., Zasadny K. R., Francis I. R., Milik A. W., Ross C. W., Moon S. D., Crawford S. M., Burgess J. M., Petry N. A., Butchko G. M., Glenn S. D., WanL R. L. Radioimmunotherapy of B-cell lymphoma with [1–131] anti-Bl (Anti-CD20) antibody. N. Engl. J. Med. 1993; 329: 459–465
   PubMed Web of Science ®Google Scholar
• Press O. W., Eary J. F., Appelbaum F. R., Martin P. J., Badger C. C., Nelp W. B., Glenn S., Butchko G., Fisher D., Porter B., Matthews D. C., Fisher L. D., Bernstein I. D. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N. Engl. J. Med. 1993; 329: 1219–1224
   PubMed Web of Science ®Google Scholar
• Grossbard M. L., Lambert J. M., Goldmacher V. S., Spector N. L., Kinsella J., Eliseo L., Coral F., Taylor J. A., Blattler W. A., Epstein C. L., Nadler L. M. Anti-B4-blocked ricin—A phase-I trial of 7-day continuous infusion in patients with B-cell neoplasms. J. Clin. Oncol. 1993; 11: 726–737
   PubMed Web of Science ®Google Scholar
• Levy R., Miller R. A. Therapy of lymphoma directed at idiotypes. Monogr. Natl. Cancer Inst. 1990; 1990: 61–68
   Google Scholar
• Horowitz M. M., Gale R. P., Sondel P. M., Goldman J. M., Kersey J., Kolb H., Rimm A. A., Ringden O., Roz-Man C., Speck B., Truitt R. L., Zwaan R. E., Bortin M. M. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555–562
   PubMed Web of Science ®Google Scholar
• Papadopoulos E. B., Ladanyi M. Donor leukocyte infusions as treatment of Epstein-Barr virus lymphoproliferative disorders in recipients of unrelated and related allogeneic transplants. Blood 1993; 10 (Suppl.).: 214a
   Google Scholar
• Segal D. M., Urch C. E., George A. J. T., Jost C. R. Bispecific antibodies in cancer treatment. Biologic-therapy of cancer updates, V. T. DeVita, S. Hellman, S. A. Rosenberg. J. B. Lippincott, Philadelphia, PA 1992; 14–12
   Google Scholar
• Depalazzo I. G., Kitson J., Gerceltaylor C., Adams S., Weiner L. M. Bispecific monoclonal antibody regulation of Fegamma RIII-directed tumor cytotoxicity by large granular lymphocytes. Cell. Immunol. 1992; 142: 338–347
   PubMed Web of Science ®Google Scholar
• Hsiehma S. T., Eaton A. M., Shi T., Ring D. B. Invitro cytotoxic targeting by human mononuclear cells and bispecific antibody-2B 1, recognizing c-erbB-2 protooncogene product and Fc gamma receptor-III. Cancer Res. 1992; 52: 6832–6839
   PubMed Web of Science ®Google Scholar
• Karpovsky B., Titus J. A., Stephany D. A., Segal D. M. Production of target-specific effector cells using hetero-cross-linked aggregates containing anti-target cell and anti-Fc gamma receptor antibodies. J. Exp. Med. 1984; 160: 1686–1701
   PubMed Web of Science ®Google Scholar
• Morganelli P. M., Kitzmiller T. J., Hemmer R., Fan-Ger M. W. Redirected targeting of LDL to human monocyte Fcgamma receptors with bispecific antibodies. Ar-terioscler. Thromb. 1992; 12: 1131–1138
   PubMedGoogle Scholar
• Titus J. A., Perez P., Kaubisch A., Garrido M. A., Segal D. M. Human K/natural killer cells targeted with hetero-cross-linked antibodies specifically lyse tumor cells in vitro and prevent tumor growth in vivo. J. Immunol. 1987; 139: 3153–3158
   PubMed Web of Science ®Google Scholar
• Jung G., Ledbetter J. A., Muller-Eberhard H. J. Induction of cytotoxicity in resting human T lymphocytes bound to tumor cells by antibody heteroconjugates. Proc. Nat. Acad. Sci. USA 1987; 84: 4611–4615
   PubMed Web of Science ®Google Scholar
• Qian J. H., Titus J. A., Andrew S. M., Mezzanzanica D., Garrido M. A., Wunderlich J. R., Segal D. M. Human peripheral blood lymphocytes targeted with bispecific antibodies release cytokines that are essential for inhibiting tumor growth. J. Immunol. 1991; 146: 3250–3256
   PubMed Web of Science ®Google Scholar
• Blankvoorthuis C. J. A.C., Braakman E., Ronteltap C. P. M., Tilly B. C., Sturm E., Warnaar S. O., Bolhuis R. L. H. Clustered CD3/TCR complexes do not transduce activation signals after bispecific monoclonal antibody-triggered lysis by cytotoxic T-lymphocytes via CD3. J. Immunol. 1993; 151: 2904–2914
   PubMed Web of Science ®Google Scholar
• Perez P., Hoffman R. W., Titus J. A., Segal D. M. Specific targeting of human peripheral blood T cells by heteroaggregates containing anti-T3 crosslinked to anti-target cell antibodies. J. Exp. Med. 1986; 163: 166–178
   PubMed Web of Science ®Google Scholar
• Glennie M. J., McBride H. M., Worth A. T., Stevenson G. T. Preparation and performance of bispecific F(ab')2 antibody containing thioether-linked Fab' fragments. J. Immunol. 1987; 139: 2367–2375
   PubMed Web of Science ®Google Scholar
• Kostelny S. A., Cole M. S., Tso J. Y. Formation of a bispecific antibody by the use of leucine zippers. J. Immunol. 1992; 148: 1547–1553
   PubMed Web of Science ®Google Scholar
• Carter P., Kelley R. F., Rodrigues M. L., Snedecor B., Covarrubias M., Velligan M. D., Wong W. L. T., Rowland A. M., Kotts C. E., Carver M. E., Yang M., Bour-Ell J. H., Shepard H. M., Henner D. High level escherichia coli expression and production of a bivalent humanized antibody fragment. Biotechnology 1992; 10: 163–167
   PubMed Web of Science ®Google Scholar
• Phelps J. L., Beidler D. E., Jue R. A., Unger B. W., Johnson M. J. Expression and characterization of a chimeric bifunctional antibody with therapeutic applications. J. Immunol. 1990; 145: 1200–1204
   PubMed Web of Science ®Google Scholar
• Staerz U. D., Bevan M. J. Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity. Proc. Natl. Acad. Sci., USA 1985; 83: 1453–1457
   Web of Science ®Google Scholar
• Kohler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495
   PubMed Web of Science ®Google Scholar
• De Lau W. B. M., Heije K., Neefjes J. J., Oosterwegel M., Rozenmuller E., Bast B. J. E.G. Absence of preferential homologous H/L chain association in hybrid hybridomas. J. Immunol. 1991; 146: 906–914
   Google Scholar
• van Dijk J., Warnaar S. O., van Eendenburg J. D., Thienpont M., Braakman E., Boot J. H., Fleuren G. J., Bolhuis R. L. Induction of tumor-cell lysis by bi-specific monoclonal antibodies recognizing renal-cell carcinoma and CD3 antigen. Int. J. Cancer 1989; 43: 344–349
   PubMed Web of Science ®Google Scholar
• Kerr L., Huntoon C., Donohue J., Leibson P. J., Bander N. H., Ghose T., Luner S. J., Vessella R., McKean D. J. Heteroconjugate antibody-directed killing of autologous human renal carcinoma cells by in vitro-activated lymphocytes. J. Immunol. 1990; 144: 4060–4067
   PubMed Web of Science ®Google Scholar
• Nistico P., Mortarini R., Demonte L. B., Mazzocchi A., Mariani M., Malavasi F., Parmiani G., Natali P. G., Anichini A. Cell retargeting by bispecific monoclonal antibodies-evidence of bypass of intratumor susceptibility to cell lysis in human melanoma. J. Clin. Invest. 1992; 90: 1093–1099
   PubMed Web of Science ®Google Scholar
• Schulz G., Bumol T. F., Reisfeld R. A. Monoclonal antibody-directed effector cells selectively lyse human melanoma cells in vitro and in vivo. Proc. Natl. Acad. Sci. USA 1983; 80: 5407–5411
   PubMed Web of Science ®Google Scholar
• Nitta T., Sato K., Okumura K., Ishii S. Induction of cytotoxicity in human T cells coated with anti-glioma x anti-CD3 bispecific antibody against human glioma cells. J. Neurosurg. 1990; 72: 476–481
   PubMed Web of Science ®Google Scholar
• Mezzanzanica D., Canevari S., Menard S., Pupa S. M., Tagliabue E., Lanzavecchia A., Colnaghi M. I. Human ovarian carcinoma lysis by cytotoxic T cells targeted by bispecific monoclonal antibodies: analysis of the antibody components. Int. J. Cancer 1988; 41: 609–615
   PubMed Web of Science ®Google Scholar
• Moller S. A., Reisfeld R. A. Bispecific-monoclonal-antibody-directed lysis of ovarian carcinoma cells by activated human lymphocytes-T. Cancer Immunol. Immunother. 1991; 33: 210–216
   PubMed Web of Science ®Google Scholar
• Nelson H., McKean D. J., Kerr L. A., Donohue J. H. Anti-tumor x anti-CD3 heteroconjugates direct human peripheral blood lymphocytes to lyse colon tumor cells. J. Surg. Res. 1990; 48: 284–290
   PubMed Web of Science ®Google Scholar
• Garrido M. A., Perez P., Titus J. A., Valdayo M. J., Winkler D. F., Barbieri S. A., Wunderlich J. R., Segal D. M. Targeted cytotoxic cells in human peripheral blood lymphocytes. J. Immunol. 1990; 144: 2891–2898
   PubMed Web of Science ®Google Scholar
• Titus J. A., Garrido M. A., Hecht T. T., Winkler D. F., Wunderlich J. R., Segal D. M. Human T cells targeted with anti-T3 cross-linked to antitumor antibody prevent tumor growth in nude mice. J. Immunol. 1987; 138: 4018–4022
   PubMed Web of Science ®Google Scholar
• Nelson H., Ramsey P. S., McKean D. J., Dozois R. R., Donohue J. H. Antitumor X anti-lymphocyte heteroconjugates augment colon tumor cell lysis in vitro and prevent tumor growth in vivo. Dis. Colon Rectum 1991; 34: 140–147
   PubMed Web of Science ®Google Scholar
• Nitta T., Sato K., Yagita H., Okumura K., Ishii S. Preliminary trial of specific targeting therapy against malignant glioma. Lancet 1990; 335: 368–371
   PubMed Web of Science ®Google Scholar
• Bolhuis R. L. H., Larners C. H. J., Goey S. H., Eggermont A. M. M., Trimbos J. B. M.Z., Stoter G., Lanzavecchia A., di Re E., Miotti S., Raspagliesi F., Rivoltini L., Colnaghi M. I. Adoptive immunotherapy of ovarian carcinoma with bs-MAb-targeted lymphocytes: a multicenter study. Int. J. Cancer 1992, Suppl. 7: 78–81
   Google Scholar
• Kroesen B. J., Terhaar A., Spakman H., Willemse P., Sleijfer D. T., Devries E. G. E., Mulder N. H., Berendsen H. H., Limburg P. C., The T. H., Deleij L. Local Antitumor treatment in carcinoma patients with bispecific-monoclonal-antibody-redirected T cells. Cancer Immunol. Immunother. 1993; 37: 400–407
   PubMed Web of Science ®Google Scholar
• Schwartz R. H. Costimulation of T-lymphocytes - The role of CD28, CTLA-4 and B7/BB1 in Interleukin-2 production and immunotherapy. Cell 1992; 71: 1065–1068
   PubMed Web of Science ®Google Scholar
• Demanet C., Brissinck J., Van Mechelen M., Leo O., Thielemans K. Treatment of murine B cell lymphoma with bispecific monoclonal antibodies (anti-idiotype x anti-CD3). J. Immunol. 1991; 147: 1091–1097
   PubMed Web of Science ®Google Scholar
• Brissinck J., Demanet C., Moser M., Leo O., Thielemans K. Treatment of mice bearing BCL1 lymphoma with bispecific antibodies. J. Immunol. 1991; 147: 4019–4026
   PubMed Web of Science ®Google Scholar
• Weiner G. J., Hillstrom J. R. Bispecific anti-idiotype/anti-CD3 antibody therapy of murine B cell lymphoma. J. Immunol. 1991; 147: 4035–4044
   PubMed Web of Science ®Google Scholar
• Weiner G. J., Kostelny S. A., Hillstrom J. R., Cole M. S., Link B. K., Wang S. L., Tso J. Y. The role of T cell activation in anti-CD3 x anti-tumor bispecific antibody therapy. J. Immunol. 1994, in press
   Web of Science ®Google Scholar
• Meeker T., Lowder J., Cleary M. L., Stewart S., Wamke R., Sklar J., Levy R. Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies. N. Engl. J. Med. 1985; 312: 1658–1665
   PubMed Web of Science ®Google Scholar
• Gravelle M., Ochi A. The targeting of CD4+ T lymphocytes to a B cell lymphoma. A comparison of anti-CD3-anti-idiotype antibody conjugates and antigen-anti-idio-type antibody conjugates. J. Immunol. 1989; 142: 4079–4084
   PubMed Web of Science ®Google Scholar
• Oshimi K., Seto T., Oshimi Y., Masuda M., Okumura K., Mizoguchi H. Increased lysis of patient CD 10-positive leukemic cells by T cells coated with anti-CD3 Fab' antibody cross-linked to anti-CDIO Fab' antibody. Blood 1991; 77: 1044–1049
   PubMed Web of Science ®Google Scholar
• Gingrich R. D., Dahle C. E., Hoskins K. F., Senneff M. J. Identification and characterization of a new surface membrane antigen found predominantly on malignant B lymphocytes. Blood 1990; 75: 2375–2387
   PubMed Web of Science ®Google Scholar
• Link B. K., Weiner G. J. Production and characterization of a bispecific IgG capable of inducing T-cell-mediated lysis of malignant B-cells. Blood 1993; 81: 3343–3349
   PubMed Web of Science ®Google Scholar
• Anderson P. M., Crist W., Hasz D., Carroll A. J., Myers D. E., Uckun F. M. G19.4 (anti-CD3) x B43(anti-CD19) monoclonal antibody heteroconjugate triggers CD19 antigen-specific lysis of t(4; 11) acute lymphoblastic leukemia cells by activated CD3 antigen-positive cytotoxic T-cells. Blood 1992; 80: 2826–2834
   PubMed Web of Science ®Google Scholar
• Haagen I. A., Van de Griend R., Clark M., Geerars A., Bast B., De Gast B. Killing of human leukaemia/ lymphoma B-cells by activated cytotoxic lymphocytes-T in the presence of a bispecific monoclonal antibody (alphaCD3/alphaCD19). Clin. Exp. Immunol. 1992; 90: 368–375
   PubMed Web of Science ®Google Scholar
• Bohlen H., Hopff T., Manzke O., Engert A., Kube D., Wickramanayake P. D., Diehl V., Tesch H. Lysis of malignant B-cells from patients with B-chronic lymphocytic leukemia by autologous T-cells activated with CD3 x CD 19 bispecific antibodies in combination with bivalent CD28 antibodies. Blood 1993; 82: 1803–1812
   PubMed Web of Science ®Google Scholar
• Bohlen H., Manzke O., Patel B., Moldenhauer G., Dor-Ken B., Vonfliedner V., Diehl V., Tesch H. Cytolysis of leukemic B-cells by T-cells activated via 2 bispecific antibodies. Cancer Res. 1993; 53: 4310–4314
   PubMed Web of Science ®Google Scholar
• Clark M., Bindon C., Dyer M., Friend P., Hale G., Cob-Bold S., Calne R., Waldmann H. The improved lytic function and in vivo efficacy of monovalent monoclonal CD3 antibodies. Eur. J. Immunol. 1989; 19: 381–388
   Google Scholar
• Clark M. R., Waldmann H. T-cell killing of target cells induced by hybrid antibodies: comparison of two bispecific monoclonal antibodies. J. Natl. Cancer Inst. 1987; 79: 1393–1401
   PubMed Web of Science ®Google Scholar
• Haagen I.-A., Geerars A. J., De Lau W. B., Clark M. R., Van de Griend R. J., Bast B., De Gast B. Killing of autologous B-lineage malignancy using CD3 x CD 19 bispecific monoclonal antibody in end stage leukemia and lymphoma. Blood 1994, in press
   PubMed Web of Science ®Google Scholar